Effective process development for viral vector-based medicines is paramount for optimized process efficiency, robustness, scalability, and product quality. Well-designed processes streamline ...

Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...

Cell and gene therapies are changing lives. They engineer patients’ cells or DNA to create personalized therapies, unlocking long-lasting or even curative treatments for diseases with high unmet needs ...

(MENAFN- EIN Presswire) EINPresswire/ -- "The landscape of viral vector development services is witnessing rapid expansion as gene and cell therapies gain traction worldwide. This sector plays a ...

CINCINNATI & COLUMBUS, Ohio--(BUSINESS WIRE)--Eikonoklastes Therapeutics, a preclinical biotech company developing treatments for today’s most challenging diseases, and Forge Biologics, a gene therapy ...

To generate successful gene therapies that are capable of delivering nucleic acids to specific cells and tissues, scientists must carefully design their products. They can employ either recombinant ...

The successes seen in a number of clinical studies on viral vector-based gene therapies (AAV, retroviral, and lentiviral vectors) are well documented, with an ever-broadening pipeline of products ...

Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...

Paul Cashen is a Senior Bioprocess Specialist at Pall, where he works on the downstream purification and analysis of viral vectors, monoclonal antibodies and recombinant proteins. From this experience ...

(MENAFN- EIN Presswire) EINPresswire/ -- What Is The Viral Vector Manufacturing Market Size And Growth? In recent years, the viral vector manufacturing market has seen a swift expansion. The market is ...

SAN DIEGO & COLUMBUS, Ohio--(BUSINESS WIRE)--Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, a ...